Please ensure Javascript is enabled for purposes of website accessibility

A Recall a Week, That's All We Ask

By Brian Orelli, PhD – Updated Apr 6, 2017 at 11:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For Johnson & Johnson, apparently that's too much.

Keep it to one recall a week. Is that too much to ask Johnson & Johnson (NYSE: JNJ)?

Instead, the health-care giant is out with its second. Earlier this week, I reported about a manufacturing problem with its contact lenses, and now Johnson & Johnson is recalling two hip- replacement devices that seem to fail at a higher-than-expected rate. And that's on top of the ongoing problems with its over-the-counter medications.

The cost of this recall won't be that huge. Johnson & Johnson had been phasing out the hip-replacement devices, so the hit to sales won't be that great. The company has agreed to pay for the surgeries of patients who will need replacements because of the recall.

Then there are the potential costs from lawsuits if plaintiffs seek damages for pain and suffering. This isn't like the children's medicines that were recalled earlier in the year when the drugs hadn't been reported to cause any serious harm. Jurors are likely to be sympathetic to frail grandmas who have to go through a seemingly needless additional surgery.

And then, of course, there's the ongoing problem of tarnishing the Johnson & Johnson name. Stryker (NYSE: SYK), Zimmer (NYSE: ZMH), and Smith & Nephew (NYSE: SNN), which all sell implants, stand to gain from this recall. The big question is how many more issues is it going to take before doctors start shunning any Johnson & Johnson product for fear that there might be a problem? Will doctors start recommending Abbott Labs' (NYSE: ABT) Humira or Pfizer (NYSE: PFE) and Amgen's (Nasdaq: AMGN) Enbrel over Johnson & Johnson's (NYSE: JNJ) Remicade simply because it's made by a company with a tainted name?

Whether we've reached that point, I don't know. Let's just hope I'm not writing about another recall next week.

Bryan Hinmon wonders if this stock is a land mine.

Johnson & Johnson is a Motley Fool Income Investor selection. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. Pfizer and Stryker are Inside Value picks. Try any of our Foolish newsletter services free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.83 (-0.57%) $0.25
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$226.87 (-0.04%) $0.10
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$99.84 (-0.83%) $0.84
Stryker Corporation Stock Quote
Stryker Corporation
SYK
$203.26 (-1.77%) $-3.67
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.70 (-0.61%) $-1.02
Smith & Nephew plc Stock Quote
Smith & Nephew plc
SNN
$22.08 (-2.08%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.